Vanguard Group Inc. Buys 1,728,453 Shares of Savara Inc. $SVRA

Vanguard Group Inc. increased its stake in shares of Savara Inc. (NASDAQ:SVRA) by 20.8% during the 4th quarter, Holdings Channel.com reports. The fund owned 10,041,647 shares of the company’s stock after purchasing an additional 1,728,453 shares during the quarter. Vanguard Group Inc.’s holdings in Savara were worth $60,551,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Rosalind Advisors Inc. grew its position in Savara by 50.7% during the 3rd quarter. Rosalind Advisors Inc. now owns 4,000,000 shares of the company’s stock worth $14,280,000 after acquiring an additional 1,345,056 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new position in Savara during the 3rd quarter worth approximately $96,000. The Manufacturers Life Insurance Company grew its position in Savara by 14.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 51,930 shares of the company’s stock worth $118,000 after acquiring an additional 6,449 shares during the last quarter. Squarepoint Ops LLC bought a new position in Savara during the 3rd quarter worth approximately $90,000. Finally, BNP Paribas Financial Markets grew its position in Savara by 86.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 25,154 shares of the company’s stock worth $90,000 after acquiring an additional 11,681 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on SVRA. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research report on Tuesday, April 21st. William Blair set a $10.00 price target on Savara in a research report on Monday, March 16th. Oppenheimer began coverage on Savara in a research report on Friday, April 24th. They set an “outperform” rating and a $11.00 price target on the stock. HC Wainwright restated a “buy” rating on shares of Savara in a research report on Monday, March 16th. Finally, Wall Street Zen lowered Savara from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $9.13.

Savara Stock Performance

SVRA opened at $5.27 on Friday. The stock has a market cap of $1.08 billion, a PE ratio of -9.41 and a beta of 0.28. The company has a quick ratio of 11.85, a current ratio of 13.47 and a debt-to-equity ratio of 0.17. The business has a 50 day moving average of $5.36 and a 200-day moving average of $5.48. Savara Inc. has a 52 week low of $1.89 and a 52 week high of $7.01.

Savara (NASDAQ:SVRA) last released its earnings results on Wednesday, May 13th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). Equities research analysts predict that Savara Inc. will post -0.51 earnings per share for the current fiscal year.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.